Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | EVP, GC, Compliance | February 01, 2023 | February 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 01, 2023 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 86,024 |
Reported balance
After 2023-02-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 69,700 · Balance 86,024 F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. F2: Includes 16,324 common shares acquired pursuant to the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2033-02-01 | Direct | 278,700 |
Reported balance
After 2023-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-01 · Grant · Acquired 278,700 · Balance 278,700 F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2: Includes 16,324 common shares acquired pursuant to the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan.
F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 3, 2023 16:10 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 278,700 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001447028-23-000007 · wf-form4_167545859079631.xml · derivative · entry 2 Howard Elizabeth · CIK 0001669530 · EVP, GC, Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,700 Underlying: Common Shares · 278,700 shares Expires 2033-02-01 F3 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:10 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 69,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-23-000007 · wf-form4_167545859079631.xml · nonDerivative · entry 1 Howard Elizabeth · CIK 0001669530 · EVP, GC, Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,024 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. F2 · balance_after: Includes 16,324 common shares acquired pursuant to the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 17:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 237,500 | $2.81 Strike: $2.81 | $667,375.00 |
DisclosureSEC source: 0001447028-22-000010 · wf-form4_164271927133471.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,500 Underlying: Common Shares · 237,500 shares Expires 2032-01-20 F1 · derivative.exercise_date: These stock options will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 16:57 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000008 · wf-form4_161359901972313.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 08:05 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 79,500 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000031 · wf-form4_158211751928342.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:06 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000432 · edgar.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Executive VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Shares · 137,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
| April 16, 2018 Filed Apr 17, 2018 20:14 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001140361-18-018856 · doc1.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Exec. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-04-16 F1 · derivative.exercise_date: The options vest as follows: 1/3 on April 16, 2019; 1/3 on April 16, 2020; and 1/3 on April 16, 2021. Read SEC document |
| March 24, 2017 Filed Apr 5, 2017 15:40 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001140361-17-014877 · doc1.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Exec. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-03-24 F1 · derivative.exercise_date: The options vest as follows: 1/3 on March 23, 2018; 1/3 on March 23, 2019; 1/3 on March 23, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.